摘要
目的：评价依泽替米贝/辛伐他汀联合用药改善冠心病患者血脂水平的疗效.方法：稳定使用辛伐他汀20mg的182例冠心病患者按数字法被随机分为：联合用药组（90例,依泽替米贝10mg＋辛伐他汀20mg）,辛伐他汀组（92例,辛伐他汀40mg）.分别在治疗前,治疗后6周评估病人的低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、总胆固醇/高密度脂蛋白胆固醇比率（TC/HDL-C）、LDL-C＜2.6mmol/L的病人比例等指标.结果：与辛伐他汀组比较,联合用药组LDL-C（-15.9％比-27.6％）、TC（-10.46％比-18.7％）和TC/HDL-C（-9.7％比-19.4％）等指标下降幅度更显著,LDL-C＜2.6 mmol/L的比例（40.2％比74.4％）显著升高,P＜0.05～0.01.两组间不良反应事件发生率差别无显著性.结论：对于单独使用辛伐他汀治疗未能达到推荐低密度脂蛋白胆固醇治疗目标的患者来说,联合依泽替米贝是一种有效的治疗方案.
Objective：To evaluate therapeutic effects of ezetimibe combined simvastatin on improving blood lipid levels in patients with coronary heart disease （CHD）.Methods：A total of 182 CHD patients,who regularly used 20mg simvastatin,were randomly divided into combined medication group （n =90,received 10mg ezetimibe ＋ 20mg simvastatin） and simvastatin group （n =92,received 40mg simvastatin） according to number table.Levels of low density lipoprotein cholesterol （LDL-C）,total cholesterol （TC）,high density lipoprotein cholesterol （HDL-C）,TC/HDL-C and percentage of patients with LDL-C〈2.6mmol/L were assessed before and six weeks after treatment.Results：Compared with simvastatin group,there were significant increase in descendent amplitude of LDL-C （-15.9% vs.-27.6%） andTC （-10.46% vs.-18.7%） levels and ratio of TC/HDL-C （-9.7% vs.-19.4%）,and significant increase in percentage of patients with LDL-C〈2.6 mmol/L （40.2% vs.74.4%） in combined medication group,P〈0.05～〈0.01.There were no significant differences in incidence rates of adverse events between two groups.Conclusion：For patients who can＇t reach the recommended therapeutic goal of low density lipoprotein cholesterol with only simvastatin,ezetimibe combined simvastatin is an effective therapeutic plan.
出处
《心血管康复医学杂志》
CAS
2014年第1期75-78,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
